GLUEHealthcareMid-Cap
Monte Rosa Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Monte Rosa Therapeutics, Inc. (GLUE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are GLUE insiders buying or selling?
Monte Rosa Therapeutics, Inc. insiders reported 17 open-market buys ($276.8M) and 30 sells ($16.1M) across 47 Form 4 filings — a net buying position of $260.7M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 17, 2026)
Total Form 4 filings
47
SEC EDGAR
Insider filers
24
Insider buys (17)
$276.8M
Insider sells (30)
$16.1M
Insider sentiment
Net buyingNet insider flow of $260.7M in net buying.
Recent GLUE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | Markus Warmuth | President & CEO | Sale | 9.5K | $23.18 | $220.2K |
| Jul 16, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 4.4K | $23.38 | $101.7K |
| Jul 7, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 6.0K | $23.31 | $139.8K |
| Jul 1, 2026 | Filip Janku | Chief Medical Officer | Sale | 5.4K | $24.50 | $132.5K |
| Jun 30, 2026 | Filip Janku | Chief Medical Officer | Sale | 6.0K | $22.95 | $137.7K |
| Jun 30, 2026 | Anthony M. Manning | Director | Sale | 10.0K | $23.11 | $231.1K |
| Jun 25, 2026 | Filip Janku | Chief Medical Officer | Sale | 41.8K | $21.08 | $882.2K |
| Jun 25, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2.2K | $20.00 | $43.5K |
| Jun 25, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 3.0K | $20.00 | $60.0K |
| Jun 18, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2.2K | $19.00 | $41.3K |
| Jun 18, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 3.0K | $19.00 | $57.0K |
| Jun 2, 2026 | Markus Warmuth | President & CEO | Sale | 5.5K | $19.44 | $106.3K |
| Jun 1, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 6.0K | $19.87 | $119.2K |
| May 28, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2.2K | $20.00 | $43.5K |
| May 26, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2.2K | $19.00 | $41.3K |
| May 22, 2026 | Anthony M. Manning | Director | Sale | 10.0K | $18.01 | $180.1K |
| May 5, 2026 | Markus Warmuth | President & CEO | Sale | 5.5K | $18.92 | $103.4K |
| Apr 15, 2026 | Markus Warmuth | President & CEO | Sale | 8.0K | $17.64 | $141.1K |
| Apr 10, 2026 | Philip Nickson | Chief Business & Legal Officer | Sale | 5.8K | $17.69 | $103.4K |
| Mar 5, 2026 | Edmund Dunn | Principal Accounting Officer | Sale | 139 | $17.96 | $2.5K |
| Mar 4, 2026 | Markus Warmuth | President & CEO | Sale | 5.5K | $17.92 | $98.0K |
| Mar 2, 2026 | Edmund Dunn | Principal Accounting Officer | Sale | 25.7K | $18.09 | $464.9K |
| Feb 24, 2026 | Filip Janku | Chief Medical Officer | Sale | 9.2K | $19.50 | $179.2K |
| Jan 9, 2026 | Markus Warmuth | President & CEO | Sale | 5.5K | $23.49 | $128.4K |
| Jun 4, 2025 | Edmund Dunn | Principal Accounting Officer | Sale | 2.1K | $4.45 | $9.2K |
Showing the 25 most recent of 47 Form 4 filings for Monte Rosa Therapeutics, Inc..
Most active GLUE insiders
- Markus Warmuth6 filings
- Edmund Dunn5 filings
- Jennifer Champoux5 filings
- Filip Janku4 filings
- Sharon Townson4 filings
Ask anything about GLUE insider activity
Use Trabud's AI agent to query Monte Rosa Therapeutics, Inc.'s Form 4 history in plain English — "Show me GLUE CEO purchases this year" or compare it against any other ticker.
Open the AI agentGLUE insider trading FAQ
Are Monte Rosa Therapeutics, Inc. insiders buying or selling?
Across 47 SEC Form 4 filings, Monte Rosa Therapeutics, Inc. (GLUE) insiders reported 17 open-market purchases totaling $276.8M and 30 sales totaling $16.1M. That is a net buying position of $260.7M.
How many insiders trade GLUE stock?
24 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Monte Rosa Therapeutics, Inc.. The most recent filing was accepted on Jul 17, 2026.
Where does Trabud get GLUE insider trading data?
All GLUE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.